28. J Enzyme Inhib Med Chem. 2018 Dec;33(1):1181-1193. doi:10.1080/14756366.2018.1490732.Synthesis and pharmacological evaluation of novel isoquinolineN-sulphonylhydrazones designed as ROCK inhibitors.Oliveira RG(1)(2), Guerra FS(2)(3), Mermelstein CDS(4), Fernandes PD(2)(3),Bastos ITS(5), Costa FN(6), Barroso RCR(5), Ferreira FF(6), Fraga CAM(1)(2).Author information: (1)a Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®),Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Riode Janeiro , Brazil.(2)b Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro ,Brazil.(3)c Laboratório de Farmacologia da Dor e da Inflamação, Instituto de CiênciasBiomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.(4)d Laboratório de Diferenciação Muscular, Instituto de Ciências Biomédicas ,Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.(5)e Instituto de Física , Universidade do Estado do Rio de Janeiro , Rio deJaneiro , Brazil.(6)f Centro de Ciências Naturais e Humanas (CCNH) , Universidade Federal do ABC(UFABC) , São Paulo , Brazil.In this study, we synthesized a new congener series of N-sulphonylhydrazonesdesigned as candidate ROCK inhibitors using the molecular hybridization of theclinically approved drug fasudil (1) and the IKK-β inhibitor LASSBio-1524 (2).Among the synthesized compounds, the N-methylated derivative 11 (LASSBio-2065)showed the best inhibitory profile for both ROCK isoforms, with IC50 values of3.1 and 3.8 µM for ROCK1 and ROCK2, respectively. Moreover, these compounds were also active in the scratch assay performed in human breast cancer MDA-MB 231cells and did not display toxicity in MTT and LDH assays. Molecular modellingstudies provided insights into the possible binding modes of theseN-sulphonylhydrazones, which present a new molecular architecture capable ofbeing optimized and developed as therapeutically useful ROCK inhibitors.DOI: 10.1080/14756366.2018.1490732 PMCID: PMC6060383PMID: 30044647  [Indexed for MEDLINE]